Allegations of fraud against Cassava Sciences (NASDAQ:SAVA) are unlikely to stop its Alzheimer’s drug candidate from quickly advancing to a Phase 3 clinical trial. As a result, I remain very bullish on SAVA stock.
Source: Shutterstock
One of the most important reasons is an issue that hasn’t been explored very much yet. Specifically, none of the allegations against Cassava relates directly to the most recent safety and cognition data on its Alzheimer candidate, simufilam.
That safety and cognition data, released on July 29, was incredibly positive, as simufilam....More>>>